Inovio Firsts

INOVIO is the first and only company to have clinically demonstrated that DNA medicines can be delivered directly into cells in the body via a proprietary smart device to produce a natural immune response robust enough to potentially treat or prevent diseases related to human papillomavirus (HPV), cancers, and infectious diseases.

To date, INOVIO clinical programs have recruited more than 2,000 patients receiving INOVIO DNA medicines in more than 6,000 applications. INOVIO’s DNA medicines have consistently activated safe, robust, and fully functional T cell and antibody responses against targeted pathogens and cancers.

HPV DNA MEDICINES

FIRST DNA medicine in Phase 3 clinical trials (VGX-3100 for precancerous cervical dysplasia caused by high-risk HPV 16/18)

FIRST to show destruction/clearance of high-risk HPV 16/18 in Phase 2b trial (VGX-3100)

FIRST DNA medicine as a potential non-surgical treatment for rare, debilitating, and potentially life-threatening recurrent respiratory papillomatosis (RRP) caused by HPV 6/11 (INO-3107)

FIRST to show complete remission in Phase 1 with two PD-1s for head and neck cancer caused by high-risk HPV 16/18 (MEDI0457, licensed out to AstraZeneca)

IMMUNO-ONCOLOGY
DNA MEDICINES

(NON HPV-ASSOCIATED)

FIRST DNA medicine to show potential for efficacy in glioblastoma multiforme (GBM), the most deadly brain cancer and one of the most aggressive cancers overall

FIRST DNA medicine to show a break in tolerance against self-antigens such as WT-1 (Wilms Tumor-1), a protein important in attacking cancer cells

FIRST DNA medicine to create anti-prostate cancer-specific T cells

INFECTIOUS DISEASE
DNA MEDICINES

(NON HPV-ASSOCIATED / EXTERNALLY FUNDED)

FIRST Lassa fever vaccine to enter clinic (INO-4500), funded by CEPI

FIRST MERS vaccine to progress to Phase 2 clinical testing (INO-4700), funded by CEPI

FIRST dMAb plasmid in Phase 1 for Zika (INO-A002), funded by Bill & Melinda Gates Foundation